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Abstract
Background:  Reelin, intensively studied as an extracellular protein that regulates brain
development, is also expressed in a variety of tissues and a circulating pool of reelin exists in adult
mammals. Here we describe the methodological and biological foundation for carrying out and
interpreting clinical studies of plasma reelin.
Results: Reelin in human plasma was sensitive to proteolysis, freeze-thawing and heating during
long-term storage, sample preparation and electrophoresis. Reelin in plasma was a dimer under
denaturing conditions. Boiling of samples resulted in laddering, suggesting that each of the 8 repeats
expressed in reelin contains a heat-labile covalent bond susceptible to breakage. Urinary-type and
tissue-type plasminogen activator converted reelin to a discrete 310 kDa fragment co-migrating
with the major immunoreactive reelin fragment seen in plasma and also detected in brain. (In
contrast, plasmin produced a spectrum of smaller unstable reelin fragments.) We examined archival
plasma of 10 pairs of age-matched male individuals differing in repeat length of a CGG repeat
polymorphism of the 5'-untranslated region of the reelin gene (both alleles < 11 repeats vs. one
allele having >11 repeats). Reelin 310 kDa band content was lower in subjects having the long
repeats in all 10 pairs, by 25% on average (p < 0.001). In contrast, no difference was noted for
amyloid precursor protein.
Conclusions: Our studies indicate the need for caution in measuring reelin in archival blood
samples, and suggest that assays of plasma reelin should take into account three dimensions that
might vary independently: a) the total amount of reelin protein; b) the relative amounts of reelin
vs. its proteolytic processing products; and c) the aggregation state of the native protein. Reelin-
plasminogen activator interactions may affect their roles in synaptic plasticity. Our results also
suggest that the human CGG repeat polymorphism affects reelin gene expression, and may affect
susceptibility to human disease.
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Background
Reelin, a protein that has features of an extracellular
matrix protein, plays a critical role in brain development
[1,2], but is also expressed in a variety of tissues and a cir-
culating pool of reelin is detectable in adult mammals. In
adult brain, reelin may act as a trophic or mobilization
factor for dendritic spines [3,4]. Circulating reelin appears
to be produced largely by the liver [5], though other
peripheral sources including plasma cells [6] make reelin
as well. Reelin in blood undergoes post-translational
processing qualitatively similar to that observed in brain
[7], and members of the reelin signaling pathway (e.g.,
dab1, alpha-3 integrin and the VLDL receptor) are
expressed in the periphery, so circulating reelin may play
some functional role invivo. There appears to be a single
reelin promoter across tissues, regulated by epigenetic
changes in promoter DNA methylation [8].
Examining reelin in the blood should provide a conven-
ient handle for correlating reelin genotype and phenotype
in humans. Reelin has been implicated in at least 3 differ-
ent human disorders: a) Humans with nonfunctional ree-
lin genes exhibit lissencephaly and profound mental
retardation [9]. b) Postmortem brains of patients with
psychosis (schizophrenia and bipolar disorder) exhibit
reelin mRNA and protein levels reduced by ~50% in every
brain region examined [10,11]. In fact, the reelin deficit is
the best replicated post-mortem neurochemical finding
documented in schizophrenia [12]. c) Reelin is a candi-
date gene for autism based on its expression in brain
regions affected in autism, its chromosomal localization,
and its large size and complex regulation [13]. Fatemi et
al. (2002) recently reported that plasma levels of reelin are
reduced in both autistic patients and unaffected family
members relative to unrelated adult controls [14].
In order to carry out and interpret studies of circulating
reelin in humans, we have characterized its molecular
properties in blood and its stability during long-term stor-
age and sample preparation. We describe processing of
reelin by two proteases present in blood, plasminogen
activator and plasmin. We also examined a biological fac-
tor that putatively may affect synthesis of reelin, namely,
a reelin gene CGG repeat polymorphism located in the 5'-
untranslated region [13,15]. Some of these results have
been presented in abstract form at the Society for Neuro-
science meeting [16,17].
Results
Methodology of Measuring Reelin in Human Plasma
We first undertook a systematic examination of the factors
affecting reelin stability in both the recombinant reelin
calibration standard as well as in human plasma. Some of
these factors could be anticipated for any large extracellu-
lar protein, but some were surprising and reflected the
unique biology of reelin.
Reelin content in plasma vs. serum
Fresh blood from 4 healthy adult male volunteers was col-
lected into standard clinical vacutainer tubes containing
EDTA (for plasma) or nothing (for serum). Blood was
immediately placed on ice, spun within 2 hours and aliq-
uoted at -80 degrees. In all fresh human samples, two ree-
lin-like immunoreactive bands were observed: the
predominant band migrated at 310 kDa, whereas a less
intense band co-migrated with full-length 420 kDa reelin
(fig. 1). Traces of a smaller reelin-like immunoreactive
band were also observed at 160 kDa. This pattern was sim-
ilar in both plasma and serum, and similar to that previ-
ously described for rat and mouse serum [5]. An antibody
against the C-terminus of reelin (H221, Santa Cruz Bio-
technology, Inc.) recognized the 420 kDa band but not
the 310 kDa band (data not shown), indicating that the
latter is truncated at the C-terminal end. After this paper
was submitted for publication, Jossin et al reported this
same finding using a different C-terminal antibody [18].
(A confirmation that all these reelin-like bands arise from
authentic reelin comes from the observation that they
were absent in the blood of patients with null mutations
in the reelin gene [9].) Plasma did not significantly differ
from serum in content of either 420 kDa or 310 kDa
bands (310 kDa band: plasma/serum ratio = 0.87 ± 0.14
s.e.m.; 420 kDa band: 0.99 ± 0.11). This suggests that the
band profile of reelin is not produced during the process
of blood clotting, and that reelin does not appreciably
associate with clots.
Stability of recombinant reelin in storage
We initially expected reelin to be stable during long-term
storage since in our hands, full-length 420 kDa reelin
appeared to be relatively stable in its native state: For
example, no detectable breakdown of reelin was observed
Reelin-immunoreactive bands seen within freshly collected  adult human plasma Figure 1
Reelin-immunoreactive bands seen within freshly collected 
adult human plasma. Loaded at 0.15, 0.3, 0.6 µl per lane and 
reacted with antibody 142.
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when plasma or reelin conditioned medium were incu-
bated at 37 degrees for 4–6 hours, even in the absence of
exogenous protease inhibitors (see fig. 4 and 7, below).
Nonetheless, degradation of reelin was detected in many
samples subjected to storage lasting weeks to months. To
understand the effects of storage in more detail, we exam-
ined aliquots of reelin conditioned medium (native vs.
fully denatured with SDS-PAGE buffer), rodent and
human plasma and serum (with or without PMSF and/or
EDTA) and soluble brain extract, at -20 or -80 degrees.
Although the rate of degradation varied considerably
across these situations, the pattern was uniform: the reelin
420 kDa band gradually became diminished or lost
entirely, the 310 kDa band appeared to be intact, and
lower molecular mass reelin-immunoreactive bands pro-
gressively increased, particularly a band migrating at 160
kDa.
A portion of this breakdown was clearly due to the action
of residual protease activity, and in the present study, pro-
tease inhibitors (PMSF 1–2 mM and EDTA 10 mM) were
added to all samples of reelin conditioned medium to be
used as calibration standards, and to archival plasma sam-
ples upon initial thawing in our laboratory. Reelin in
plasma and serum samples appeared to be more stable
than in conditioned medium, in that some samples
showed intact full-length reelin bands even after long-
term storage for 4–7 years. Possibly this is due to the pres-
ence of endogenous protease inhibitors in blood, or circu-
lating reelin may be protected against proteolysis by its
conformation or binding to other proteins. However,
repeated freezing and thawing of samples caused a pro-
gressive loss of the 420 kDa band even when protease
inhibitors were present, and in our experience, the effect
of thawing was more detrimental to the quality of reelin
bands in plasma than storage time per se. In the present
study, reelin used as calibration standard was only thawed
once, and care was taken that archival samples of human
plasma were thawed in parallel.
Excessive heating causes fragmentation of reelin Figure 2
Excessive heating causes fragmentation of reelin. Immunoblot of recombinant reelin loaded in duplicate on a 6.5% acry-
lamide resolving gel with 4% stacking gel, reacted with antibody 142. Samples were prepared by adding SDS-PAGE buffer and 
DTT and heating at 100 C for the following times: 1 no heat, 2 1 min, 3 3 min, 4 10 min, 5 30 min. Heating resulted in progres-
sive breakdown of reelin into a ladder of 6 additional fragments migrating between 160 and 310 kDa, plus some smaller 
fragments.





79 kDaBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/9
Page 4 of 13
(page number not for citation purposes)
Most surprisingly, reelin was highly sensitive to boiling
during sample preparation. Prolonged heating resulted in
nearly complete breakdown of reelin into a ladder of dif-
ferent sized fragments, and detectable laddering could be
observed even after boiling as short as 1–3 minutes (fig.
2). The sizes and number of the fragments between 160
and 310 kDa suggest that each of the 8 repeats expressed
in reelin [1,2] contains a heat-labile covalent bond sus-
ceptible to breakage. For this reason, in the present study,
sample boiling time was rigorously minimized and con-
trolled, and all sample pairs to be compared were treated
in parallel. We even noted breakdown of reelin when
Reelin is a covalent dimer Figure 3
Reelin is a covalent dimer. a) Recombinant reelin samples were prepared by adding SDS-PAGE buffer with or without 
DTT or boiling prior to loading in duplicate on a 6.5% acrylamide gel with 4% stacking gel, reacted with antibody 142. 1 no 
DTT, no boiling; 2 no DTT, 3 min boiling ; 3 DTT, no boiling ; 4 DTT, 3 min boiling. b) Immunoblot of proteins prepared by 
adding SDS-PAGE buffer without DTT but with 3 min boiling, loaded on an agarose-acrylamide composite gel. Lanes 1–3, 
reacted with antibody 142. 1 recombinant reelin, 2 human plasma, 3 human serum, 4 laminin, reacted with anti-laminin 
antibody.
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electrophoresis was allowed to proceed at a voltage that
created excessive heat. Nevertheless, heating was not
omitted entirely since boiling reelin in SDS-PAGE buffer
for a minute or two under reducing conditions improved
its resolution in SDS-PAGE electrophoresis (see fig. 3a
below).
Biology of Reelin in Human Plasma
Native reelin is at least a dimer
Several lines of evidence indicate that reelin, within trans-
fectant conditioned medium and plasma, is at least a
dimer in its native state. First, native reelin is completely
cleared from conditioned medium when centrifuged for 2
hours at 200,000 × g (data not shown). Second, when
Reelin is a substrate for plasminogen activator (uPA) Figure 4
Reelin is a substrate for plasminogen activator (uPA). a) Lanes 1 and 8, recombinant reelin standard. Lanes 2–4, incu-
bated at 37 degrees for 2 10 min, 3 30 min, 4 6 h (negative controls). Lanes 5–7, incubated in the presence of uPA (3 units/ml) 
for 5 10 min, 6 30 min, 7 6 h. b) Lane 1, recombinant reelin standard. Lanes 2 and 3, incubated for 6 h in the presence of uPA. 
2 digestion in the absence of plasminogen activator inhibitor-1 (PAI-1) and 3 digestion in the presence of PAI-1 (Calbiochem, 
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disulfide bonds were not reduced, reelin failed to enter
SDS-PAGE resolving gels and most of the material
remained at the top of the stacking gel (fig. 3a). Nonre-
duced reelin comigrated with nonreduced EHS laminin
(~900 kDa) in agarose-acrylamide composite gels, sug-
gesting that it is a dimer (fig. 3b). These data confirm and
extend the findings of Kubo et al. (2002) by showing that
native reelin is a dimer not only in brain but also in
plasma [19]. Because of the possibility that reelin in clin-
ical samples might form multimers that remain cross-
linked even after reduction of disulfide bonds, in the
present study, both the stacking gel and resolving gel were
examined during Western blotting analyses.
Reelin is a substrate for plasminogen activator and plasmin
Recombinant native reelin was an excellent substrate for
plasminogen activator, provided that the transfectant con-
ditioned medium was concentrated (25–40-fold on Cen-
tricon filters with MW 100,000 cut-off) so that the
concentration of reelin was above ~50 nM. As shown in
fig. 4a, urokinase-type plasminogen activator (uPA; Fluka,
from human kidney cells, E.C. 3.4.21.73) completely con-
verted full-length 420 kDa reelin to a single 310 kDa frag-
ment that comigrated with the major reelin-
immunoreactive fragment seen in serum and plasma.
Digestion of reelin with tissue-specific plasminogen acti-
vator (tPA) also generated a single 310 kDa fragment (not
shown). The digestion by uPA was inhibited specifically
by plasminogen activator inhibitor-1 (PAI-1) (fig. 4b).
The major reelin band seen endogenously in blood or
produced by uPA digestion migrated under nonreducing
conditions in agarose-acrylamide composite gels at an
apparent molecular size larger than reelin monomer but
smaller than intact reelin dimer (fig 3b), suggesting that it
represents a dimer of truncated reelin chains. Consistent
with this, uPA-digested reelin failed to react with an anti-
reelin antibody that recognizes the C-terminus (data not
shown). These findings indicate that uPA cleaves reelin at
a site ~3/4 of the way to the C-terminus, and that the ree-
lin-reelin dimerization site is located N-terminal to this
cleavage site. uPA-cleaved reelin retained the ability to
bind the VLDL receptor in ELISA assay (fig. 5). In contrast,
plasmin (Sigma, from human plasma, E.C. 3.4.21.7) pro-
duced a spectrum of reelin fragments that became
progressively smaller with increasing digestion time (fig.
6). The effects of plasmin were inhibited specifically by
aprotinin (fig. 6).
Surprisingly, the cation chelator EDTA increased the sus-
ceptibility of reelin to uPA and plasmin, both in terms of
generating additional fragments and in terms of causing
more rapid digestion (fig. 7). EDTA did not lead to frag-
mentation of reelin unless exogenous proteases were
added. Since the proteases themselves are thought to be
cation-independent, this finding raises the possibility that
calcium or other cations may bind to native reelin and
help to maintain its normal conformation; when the cati-
ons are removed, reelin may be opened up, thus revealing
more sites for protease attack. Although the underlying
mechanism is unclear, this finding has methodologic
implications, since plasma is often collected in tubes con-
taining calcium chelators; it is possible that reelin break-
down will actually be accelerated under these conditions
unless serine protease inhibitors are also present in the
tubes.
Relative plasma reelin content as a function of reelin 
genotype (CGG repeat length)
The human reelin gene has several features suggesting that
the 5'-untranslated region regulates gene expression. The
initial ATG is bypassed for initiating translation [20], but
more importantly, 4–23 CGG repeats are immediately
upstream of the initiator methionine codon [15]. The
repeats are polymorphic in some, but not all, human pop-
ulations [13,21,22]. Persico et al. (2001) studied families
with primary autistic probands, and found that even
Full-length reelin and uPA-treated reelin both bind to immo- bilized VLDL receptor ligand binding domain (sVLDLr1-8) Figure 5
Full-length reelin and uPA-treated reelin both bind 
to immobilized VLDL receptor ligand binding 
domain (sVLDLr1-8). 100 µl soluble sVLDLr1-8 (4 µg/mL; 
characterized in Hembrough et al., 2001 [37]) was coated in 
microtiter wells overnight at 4 C. The wells were then 
blocked with BSA (30 mg/mL). Following washing, the wells 
were incubated with conditioned media containing full-length 
reelin (circles) or uPA-digested reelin (squares). Bound reelin 
was detected using anti-reelin antibody G10 and goat anti-
mouse IgG conjugated to alkaline phosphatase. Each data 
point represents the average of duplicate determinations. 
sVLDLr coated wells are shown with closed symbols, while 
BSA coated wells are shown with open symbols.
Dilution























0.6BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/9
Page 7 of 13
(page number not for citation purposes)
though most autistic patients do not possess long CGG
repeats (≥ 11 repeats in at least one allele), the long alleles
were preferentially passed to autistic offspring, such that
the long CGG repeats were associated with a two-fold
increase in the risk of autism [13]. The effect was more
pronounced in North American populations than in
European cohorts. Recently, Zhang et al. (2002) replicated
this finding on a different set of North American multi-
plex autistic pedigrees [21], and a separate study con-
firmed weaker or no association of CGG repeat length
with autism in European populations [23].
A central, basic question is whether the human CGG
repeat polymorphism has functional consequences for
reelin production. To address this question, we compared
reelin levels in plasma from individuals differing in reelin
CGG repeat length.
Linearity and statistical reliability of the assay
When loading different amounts of the reelin calibration
standard on gels, the Western blotting assay was linear
over at least a 5–10 fold range (fig. 8a). In contrast, when
serum or plasma was loaded, the assay reached saturation
over a narrower 3–4 fold range – that is, whereas reelin
can be detected within as little as 0.15 microliters of
plasma loaded per lane, the reelin band intensities start to
saturate at ~0.6 microliters of plasma loaded (fig. 8a). In
fact, when too much plasma is loaded, the band ODs did
not simply level off but actually decreased (not shown).
Therefore, in the present study, each sample was loaded at
3 different amounts to verify linearity, and compared
against 3 different loadings of its paired sample and 3 dif-
ferent loadings of the reelin calibration standard run in
parallel on the same gel. To estimate the inherent reliabil-
ity of the assay, and to ensure that there was no inherent
bias in the apparatus used in the study, the reelin calibra-
tion standard was loaded 3 times per gel in 4 different gels
and assayed for reelin content. There was no difference in
reelin content estimated for samples run on the left vs. the
right side of blots (mean ratio = 1.01 ± 0.06).
Assays on archival samples
Archival samples of plasma were studied which were char-
acterized in the earlier study of Persico et al. (2001) [13].
Because the samples had been subjected to several prior
freeze-thaws (see above), the full-length reelin band could
not be measured; however, the 310 kDa reelin bands were
intact and there was no sign of further degradation (i.e.,
only traces were seen of 160 kDa and lower reelin-immu-
noreactive bands) (fig. 8c). Thus, it was possible to ask
Reelin is a substrate for plasmin Figure 6
Reelin is a substrate for plasmin. Recombinant reelin was digested with plasmin (Sigma, from human plasma, 0.5 unit/ml) 
for various times, loaded in duplicate and immunoblotted. 1 no incubation, 2 10 min, 3 30 min, 4 6 h, 5 digested for 6 h in the 
presence of aprotinin (Sigma, 40 µM).
1            2           3           4                5     
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whether the relative content of the 310 kDa reelin band
varied according to the number of CGG repeats present in
the 5'-untranslated region of the reelin gene. Ten pairs of
male autistic patients, ranging between 4–16 years of age,
were tested. All families were singletons, so no autistic
pairs were sibs. In each pair, one member had both alleles
within the "normal range," i.e., 8/8, 8/10 or 10/10 geno-
types, whereas the other had 12 or more CGG repeats on
one or both alleles (Table 1). The second member of the
pair had a higher overall number of CGG repeats in all but
one case (the exception had 10/10 vs. 8/12 repeats, where
10+10 = 8+12). The plasma protein concentration was
measured in half of the patient samples, and did not differ
among first and second members of the pairs. All samples
were assayed and measured by observers who were una-
ware of genotype. All human plasma samples were
assayed twice in independent tests; shown here are the
results averaged over the two assays (note that results were
also statistically significant for each assay considered
separately).
As shown in Table 1 and fig. 8b, in ten out of ten cases, the
sample from patients with longer CGG repeat length
expressed less plasma reelin 310 kDa than their matched
counterparts having CGG repeat length within the normal
range. On average, the samples having at least one allele
with 12 or more repeats had 24.5% ± 3.8% less than its
paired control; this difference was significant at p < 0.001
by both two-tailed t-test (paired) and one-way ANOVA. As
a control, we re-blotted the same blots with antibodies
directed against the N-terminus of amyloid precursor pro-
tein (APP), which is an endogenous blood component
and migrates in plasma predominantly as a 180 kDa band
(fig. 8d). The APP assay was technically satisfactory (i.e.,
the band intensity curves increased linearly as more
plasma was loaded), but no consistent pairwise difference
was seen in relative content of APP (Table 1; mean ratio
was 0.99 ± 0.07). As well, within individual pairs, the
relative plasma reelin content showed no significant cor-
relation with relative APP content (r = 0.01).
EDTA increases the susceptibility of reelin to uPA and plasmin Figure 7
EDTA increases the susceptibility of reelin to uPA and plasmin. Recombinant reelin was incubated with proteases for 
6 hrs. and immunoblotted. 1 reelin standard, 2 treated with uPA, 3 treated with uPA in the presence of 10 mM EDTA. 4 reelin 
standard, 5–6 treated with plasmin (0.5 unit/ml) for 1 and 6 h, 7 treated with plasmin 6 h in the presence of 10 mM EDTA. 
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Discussion
Our studies indicate that assays of plasma reelin should
take into account three independent dimensions: a) the
total amount of reelin protein; b) the relative amounts of
reelin vs. its proteolytic processing products; and c) the
aggregation state of the native protein. We found that
recombinant and circulating reelin are both expressed pri-
marily as dimers when assayed under denaturing condi-
tions that disrupt non-covalent bonds. However, the
observation that native reelin could be pelleted by ultra-
centrifugation raises the possibility that reelin also forms
larger non-covalent multimers or molecular aggregates in
vivo. Reelin has been reported to have intrinsic serine pro-
tease activity [20], and we show here that reelin is a sub-
strate for plasminogen activator and plasmin,
endogenous components of blood [17]. Hence it is
important that clinical samples are collected, stored and
handled in parallel and in the presence of protease
Assay of reelin within archival clinical samples Figure 8
Assay of reelin within archival clinical samples. a) Graph of immunoblot band intensity vs. volume loaded for recom-
binant reelin (solid) and human plasma (open). b) "Raw" 310 kDa reelin band optical density scores from samples assayed pair-
wise (patient having only ≤10 CGG repeats vs. having at least one allele > 10 repeats; shown are the values for 0.37 µl plasma 
loaded per lane) as described in the text and summarized as ratios in Table 1. Overall, the ''short'' repeat group had raw optical 
density scores of 22.3 ± 0.87 s.e.m. whereas the ''long'' repeat group had 16.9 ± 1.2. c) Assay from patient pair #4 (Table 1). 
The patient having genotype 8/8 is on the left, and having 8/13 is on the right; each is loaded at 0.15, 0.3, 0.6 µl per lane and 
blotted with antibody 142. The lane at the far left is recombinant reelin standard. d) The same blot was reblotted with anti-
body directed against the N-terminus of amyloid precursor protein (APP), revealing a band migrating at 180 kDa.
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inhibitors. Reelin is very sensitive to repeated freeze-thaw-
ing and conversely, appears to contain heat-labile bonds
within its repeats, suggesting that heating samples prior to
electrophoresis must be limited and rigorously
controlled.
The finding that plasminogen activators convert reelin to
a single 310 kDa processed form is intriguing for several
reasons. First, the 310 kDa form is the major reelin-immu-
noreactive fragment expressed in blood, and is likely to be
functional insofar as it retains the ability to bind at least
one putative receptor, namely, the VLDL receptor (fig. 5);
see also [18]. Second, tPA and uPA have an extremely
narrow substrate specificity, and have been shown to act
directly upon only a handful of proteins (notably plas-
minogen and hepatocyte growth factor); in these cases,
they activate functional states of the proteins. Third, like
reelin, plasminogen activator has been strongly impli-
cated in regulating neuronal migration [1,2,25], synaptic
plasticity [3,4,26] and long-term potentiation [27,28].
Further studies are needed to test the hypothesis that
processing of reelin by tPA or uPA "activates" some of its
invivo functions, and that some of the effects of plasmino-
gen activators on neural development and function may
be mediated via reelin.
Our study underscores the need to judge the suitability of
archival blood samples carefully. In our hands, recom-
binant reelin and serum samples only showed prominent
160 kDa bands when the Western blot transfer was
incomplete (so that high molecular weight bands did not
transfer well) or when the samples had undergone exten-
sive degradation. Although the archival samples studied
here did not show those features, due to previous freeze-
thawings the 420 kDa band was lost and so they were not
suitable for assessing overall content of reelin. As well,
patients and their family members were not well matched
for age or gender in this series. Thus, we are not in a posi-
tion to make any inference concerning whether circulat-
ing reelin content differs in autistics vs. unaffected
individuals (siblings or parents).
On the other hand, it is striking that reelin CGG repeat
genotype and 310 kDa band phenotype could be clearly
correlated, using a group of individuals matched for age,
gender and diagnosis (i.e., autistic patients). This suggests
that reelin levels are relatively stable and do not fluctuate
markedly as a function of extraneous variables (e.g., time
of day or feeding status). This is also consistent with other
preliminary studies suggesting that circulating reelin lev-
els within an individual are relatively constant over a
period of weeks, though may vary systematically with age
(N. Smalheiser, unpublished observations.) Therefore,
despite the limitations of archival samples, we can safely
conclude that the CGG polymorphism in the reelin 5'-
untranslated region is not neutral, but affects reelin syn-
thesis in humans.
The extent of the CGG-related decrease in reelin expres-
sion observed in blood, ~25%, might not suffice to pro-
duce overt abnormalities in brain development or
functioning. However, such a decrease may render an
individual more susceptible to the additive or synergistic
effects of other factors (e.g., prenatal insults [29]) that sep-
arately affect reelin expression. Reeler heterozygous mice,
which express 50% of wild-type reelin levels in brain and
blood [5], exhibit anatomical and behavioral abnormali-
ties [30–32], suggesting that even partial reelin deficits
may be of pathologic significance. The CGG repeat poly-
morphism, being in the 5'-untranslated region of the ree-
lin gene, is poised to affect reelin levels via transcription
whereas it is difficult to see how it could alter protein
structure, processing or stability. Persico et al. have trans-
fected neural and non-neural cell types with 4–13 CGG
repeats upstream of luciferase reporter constructs; they
have found that constructs with 4 repeats produce more
luciferase than those with 8–10 repeats, and these in turn
produce 25–50% more than those with 12 or 13 repeats
Table 1: 
Sample Pair Reelin Genotypes Ages APP Ratio Reelin Ratio
1. 8/8 vs. 10/13 5 – 10 1.29 0.66
2. 10/10 vs. 8/12 5 – 11 1.04 0.87
3. 8/8 vs. 13/13 7 – 5 0.98 0.85
4. 8/8 vs. 8/13 16 – 10 0.97 0.95
5. 10/10 vs. 10/14 5 – 5 0.77 0.77
6. 10/10 vs. 10/13 5 – 4 0.66 0.53
7. 8/10 vs. 10/23 6 – 13 0.88 0.79
8. 10/10 vs. 10/13 5 – 6 1.18 0.70
9. 8/10 vs. 10/12 5 – 5 1.03 0.70
10. 8/10 vs. 12/13 6 – 4 1.37 0.75BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/9
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(A. M. Persico and A. Pimenta, manuscript in prepara-
tion). This strongly suggests that CGG repeat length affects
transcription. However, the relationship between CGG
repeat length and reelin expression remains to be under-
stood in detail, and possibly may differ between brain and
periphery. The reelin promoter also appears to be regu-
lated by methylation [8], which may interact with the
CGG polymorphism and deserves further attention.
Methods
To make recombinant reelin, full-length mouse reelin
cDNA [33] in plasmid pCrl or pCrlM (lacking or contain-
ing a Myc epitope; gift of Dr. Gabriella D'Arcangelo, Bay-
lor College of Medicine) was transfected into 293T cells
(gift of Dr. Brian Howell, NIH) using Lipofectamine 2000
(Gibco). Following transfection in minimal DMEM
medium for 6 h, cells were rinsed and placed in serum-
free Neurobasal/B27 medium (Gibco). Every two days,
the conditioned medium was removed and replaced with
fresh medium for up to two weeks; in some cases, Vector-
stat (Genespan Corp.) was added to improve the yield. As
a negative control, cells were transfected with a plasmid
lacking insert and conditioned medium was harvested in
parallel. Conditioned medium was spun to remove cellu-
lar debris, PMSF (1 mM) and EDTA (10 mM) were added
as protease inhibitors, and aliquots were frozen at -80
degrees. To make reelin calibration standard, equal vol-
umes of conditioned medium were mixed with SDS-
PAGE sample buffer containing DTT (final concentration
4% SDS and 1% DTT), and stocks were aliquoted and
stored at -80 degrees.
To examine reelin and its content within human plasma,
plasma (4 µl) was diluted 20-fold with SDS-PAGE sample
buffer containing 1% DTT and boiled (3 min) prior to
loading. Samples were separated on 6.5% SDS-PAGE
resolving gels (with 4% stacking gel) according to Lae-
mmli [34], run in parallel with Bio-Rad high-molecular-
weight prestained standards, and transferred to PVDF
membranes (Hybond-P, Amersham) as described [35].
Blots were blocked in 1% non-fat dry milk for 1 h at room
temperature, incubated in monoclonal mouse anti-reelin
antibody 142 (1:2500 in blocker; gift of Dr. André Goffi-
net, Univ. of Louvain, Belgium) overnight at 4 degrees,
rinsed, incubated in secondary antibody (1:5,000, peroxi-
dase-conjugated anti-mouse IgG, affinity purified, Chemi-
con) for 2–3 h, rinsed, incubated in enhanced
chemiluminescence reagent (ECL-Plus, Amersham) for 5
min, and exposed to film (Hyperfilm ECL; Amersham) for
15 min. In the present study, the primary antibody (anti-
reelin 142) was purified from crude ascites using protein
G chromatography; this greatly reduced background of
the Western blots, without loss of sensitivity. As indicated,
in some experiments recombinant reelin was immunob-
lotted using anti-reelin antibody G10 ascites (1:5,000; gift
of Dr. Andre Goffinet, Univ. of Louvain, Belgium). Anti-
body 142 and G10 both recognize epitopes near the N-ter-
minus of reelin [36]; whereas antibody 142 recognizes
both human and rodent reelin, G10 recognizes rodent
reelin extremely well but barely recognizes human reelin.
To detect other antigens present on these blots, no "strip-
ping" was performed. Blots were simply re-wetted in
methanol, rinsed in water, and then re-blocked and
immunoblotted as above, using either polyclonal goat
anti-amyloid precursor protein (APP) (1: 770; recognizing
amino acids 44–63, Chemicon, Temecula, CA) or polyclo-
nal rabbit anti-laminin (1: 50,000; Sigma), followed by
peroxidase conjugated anti-goat IgG (1:50,000; Chemi-
con) or anti-rabbit IgG (1: 50,000; Sigma).
To examine the molecular size of non-reduced reelin in
composite agarose-acrylamide gels, agarose (0.4–0.6%,
w/v, electrophoresis grade, BRL) was melted in electro-
phoresis buffer (40 mM Tris-acetate, pH 7.8, 0.1% SDS, 1
mM EDTA) until clear, allowed to cool to 55 C, added
30% acrylamide-0.8% bisacrylamide, 1:200 10% APS and
1:2000 TEMED and poured in the Mini-PROTEAN 3 ver-
tical apparatus (Bio-Rad). The percentage of acrylamide
was varied from 1–3% in different experiments; optimal
band resolution was observed using agarose (0.5%) and
acrylamide (2.75%). Before adding samples, the gel was
incubated at 4 C for 30 min in electrophoresis buffer.
Samples were electrophoresed at 30 milliamp for 30 min,
then at 50 milliamp until the 205 kDa prestained
molecular weight standard was just below the middle of
the gel. To minimize heating, the gel apparatus was
packed in wet ice. Proteins were transferred to PVDF
membrane overnight at 14 volt (70 milliamp, constant
current conditions), at 4 C.
Plasma assays correlating reelin genotype and phenotype
utilized archival samples collected from primary autistic
probands screened for known causes of autism and char-
acterized in detail as described [13]. Written informed
consent was provided by parents regarding the use of
plasma for these assays, and all studies had IRB approval.
All patient samples were from children (range 5–16 years
old) matched for sex (males) and pairs were chosen to
match age as closely as possible. To compare the intensi-
ties of immunoreactive protein bands between autistic
pairs differing in CGG repeat length, each sample was
loaded at three different volumes and pairs were loaded
on the same gel. Integrated optical densities were meas-
ured for each band using a high resolution scanner and
NIH Image 1.62 image processing program, taking into
account the area of the band and subtracting the back-
ground value for each lane. For each sample, the optical
densities were plotted as a function of volume loaded.
Experiments were analyzed in which the optical densityBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/9
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curves are linear and not saturated, where there is overlap
between the paired sample curves, and where the slopes of
the curve for the major plasma reelin fragment (310 kDa)
are approximately parallel. Then, the relative amount of
reelin present in the plasma sample is estimated by inter-
polation between the paired sample curves.
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